Resources for You
Relenza (zanamivir) Information
Relenza (zanamivir) is approved for treatment of acute uncomplicated illness due to influenza A and B in patients 7 years of age and older. It is also approved for preventive use (prophylaxis) in patients 5 years of age and older.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.